Dr. Ryuji Ueno is Chairman of the Board, Chief Executive Officer, Chief Scientific Officer of Sucampo Pharmaceuticals, Inc. Dr. Ueno cofounded affiliate RTech in September 1989 and served as its President from 1989 to March 2003. Dr. Ueno also cofounded whollyowned subsidiary, Sucampo AG, or SAG, in December 1997 and served as its Chairman of the Board or Vice Chairman of the Board since its inception. Dr. Ueno received his M.D. and a Ph.D. in medicinal chemistry from Keio University in Japan, and he received a Ph.D. in Pharmacology from Osaka University
Chairman of the Board, CEO, Chief Scientific Officer
Age: 58 Chairman Since 2007 Ph.D
|Ueno is married to Dr. Sachiko Kuno, one of founders and a controlling stockholder of S&R Technology Holdings, LLC, or S&R, which owns a majority of stock.|
The company has return on total asset (ROA) of 3.64 % which means that it generated profit of $3.64 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 11.85 % meaning that it created $11.85 on every $100 dollars invested by stockholders.
The company currently holds 52.85 M in liabilities with Debt to Equity (D/E) ratio of 1.23 which is about average as compared to similar companies. Sucampo Pharmaceuticals Inc has Current Ratio of 2.27 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Entity SummarySucampo Pharmaceuticals, Inc., a pharmaceutical company, focuses on the research, discovery, development, and commercialization of proprietary drugs based on prostones and other novel drug technologies in the Americas, Europe, and Asia. Sucampo Pharmaceuticals Inc [SCMP] is traded on NASDAQ General Markets in USA. It is located in Sucampo Pharmaceuticals, Inc.Bethesda, MD and employs 128 people. Filter other
|Click to run this filter|| |
Filter Other Insiders
| SCMP Nasdaq
Sucampo Pharmaceuticals Inc
Currency: USD - US Dollar
Traded on NASDAQ General Markets
Sucampo Pharmaceuticals Inc has less than 16.16 (%) percent chance of experiencing financial distress in the next 2 years of operations.
Sucampo price boundaries
Promote Sucampo and Ryuji Ueno